Replies to post #19716 on Relief Therapeutics Holding AG (RLFTF)

[massulo52]

Fast track for IV, I'm sure that when this is approved the inhaler study should prove positive quickly

[dmsrz8]

Ok. For those that are not reading well. This study in Europe is not the inhaler study being conducted here in the US. The one in the IS has a much shorter turnaround. The current IV study is set to conclude in October or sooner depending on enrollment speed.

[trademax42]

This post explains:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158056929

This looks like a brand new study on clinical trials that came out today. This is to prevent ARDS who has covid-19. "Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS". Its being led by a sponsor, not by relief. I believe this is being run in a small city in Switzerland. I believe this is a phase I study.

ClinicalTrials.gov Identifier: NCT04536350

https://clinicaltrials.gov/ct2/show/NCT04536350?term=Aviptadil&draw=2&rank=1

Correct me if I'm wrong. This may not be the same pivotal study slated for inhaled version to start soon. Read here from Relief web site:

Patients with COVID-19 induced non-Acute Lung Injury who have demonstrated reduction in blood oxygenation, dyspnea, and exercise intolerance but do not require endotracheal intubation and mechanical ventilation will be treated with Aviptadil plus Standard of Care vs. placebo, plus Standard of Care. Patients will be randomized to inhaled Aviptadil, 100 µg/inhalation, 3x daily vs. placebo 3x daily. The primary outcome will be progression to ARDS over 28 days. Estimated Study Completion Date: October 1, 2020

Further details on Clinical Trials.gov, identifier NCT04360096


Notice different study identifiers too.

https://relieftherapeutics.com/clinical-trials-2/


Quote from your post:

I don't get it "March 2022". That is not a fast track. I thought we would get approved by end of Sep.

$RLFTF

Disclaimer: This is in my opinion only, do your own dd.